Literature DB >> 11000253

Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

R A Otten1, D K Smith, D R Adams, J K Pullium, E Jackson, C N Kim, H Jaffe, R Janssen, S Butera, T M Folks.   

Abstract

Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (HIV) was investigated using the HIV type 2 (HIV-2)/pig-tailed macaque transmission model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-2 exposure. Systemic infection was not evident in the 12- and 36-h groups, as defined by plasma viremia, cell-associated provirus, antibody responses, and lymph node virus. Breakthrough infection in the 72-h group was detected at week 16 post-virus exposure. These results demonstrate for the first time using a vaginal transmission model that early intervention after high-risk sexual exposures may prevent infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000253      PMCID: PMC112413          DOI: 10.1128/jvi.74.20.9771-9775.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact.

Authors:  T E Mertens; E Belsey; R L Stoneburner; D L Beer; P Sato; A Burton; M H Merson
Journal:  AIDS       Date:  1995       Impact factor: 4.177

Review 2.  Probabilities of sexual HIV-1 transmission.

Authors:  T D Mastro; I de Vincenzi
Journal:  AIDS       Date:  1996       Impact factor: 4.177

3.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model.

Authors:  R A Otten; D L Ellenberger; D R Adams; C A Fridlund; E Jackson; D Pieniazek; M A Rayfield
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast.

Authors:  J N Nkengasong; L Kestens; P D Ghys; S Koblavi-Dème; R A Otten; C Bilé; C Maurice; M Kalou; M Laga; S Z Wiktor; A E Greenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

6.  Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina.

Authors:  R A Otten; B G Brown; M Simon; L D Lupo; B S Parekh; M D Lairmore; C A Schable; G Schochetman; M A Rayfield
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

7.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

8.  Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia.

Authors:  C J Miller; M Marthas; J Torten; N J Alexander; J P Moore; G F Doncel; A G Hendrickx
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

9.  Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-12-22       Impact factor: 17.586

10.  Intrarectal transmission of simian immunodeficiency virus in rhesus macaques: selective amplification and host responses to transient or persistent viremia.

Authors:  P Trivedi; D Horejsh; S B Hinds; I I Hinds PW; M S Wu; M S Salvato; C D Pauza
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  47 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

Review 2.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

3.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Authors:  Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

4.  Nonoccupational Postexposure Human Immunodeficiency Virus Prophylaxis: Acceptance Following Sexual Assault.

Authors:  Jessica E Draughon Moret; William E Hauda; Bonnie Price; Daniel J Sheridan
Journal:  Nurs Res       Date:  2016 Jan-Feb       Impact factor: 2.381

5.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

6.  Deep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activation.

Authors:  Fredrik Barrenas; Robert E Palermo; Brian Agricola; Michael B Agy; Lauri Aicher; Victoria Carter; Leon Flanary; Richard R Green; Randy McLain; Qingsheng Li; Wuxun Lu; Robert Murnane; Xinxia Peng; Matthew J Thomas; Jeffrey M Weiss; David M Anderson; Michael G Katze
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

7.  Nonpathogenic CCR2-tropic SIVrcm after serial passage and its effect on SIVmac infection of Indian rhesus macaques.

Authors:  Binhua Ling; Ronald S Veazey; Preston A Marx
Journal:  Virology       Date:  2008-07-26       Impact factor: 3.616

Review 8.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

Review 9.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

10.  Gender Reassignment Surgery in Human Immunodeficiency Virus-Positive Patients: A Report of Two Cases.

Authors:  Seok-Kwun Kim; Ji-An Choi; Myung-Hoon Kim; Min-Su Kim; Keun-Cheol Lee
Journal:  Arch Plast Surg       Date:  2015-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.